Can a new antibody calm severe eczema?

NCT ID NCT07103174

Completed Disease control Sponsor: Shanghai Mabgeek Biotech.Co.Ltd Source: ClinicalTrials.gov ↗

First seen Aug 03, 2026 · Last updated Aug 04, 2026 · Updated 1 time

Summary

This phase II trial is testing whether an experimental drug called MG-K10 can reduce the severity of moderate-to-severe atopic dermatitis, a chronic inflammatory skin condition. About 60 adults who have not responded well to topical treatments will receive either MG-K10 or a placebo via injection. The study measures how many participants achieve significant skin improvement after 24 weeks, as well as the drug's safety and how the body processes it.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: MG-K10, an experimental humanized monoclonal antibody given by injection
What this could lead to: If successful, MG-K10 could offer a new treatment option for people with moderate-to-severe atopic dermatitis who do not get enough relief from topical creams.
What could go wrong: This is an early-phase trial with only 60 participants, so results may not apply to everyone. The drug may not work as hoped or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS (AD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atopic eczema

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ATOPIC DERMATITIS (AD)

Contacts and locations

Locations

Hangzhou First People's Hospital

Zhejiang, 杭州, 310000, China
Tower 5,No.34,Chunxiao Road No.122 Pudong District, Shanghai, 201203.p R. china

Shanghai, Shanghai Municipality, 201203, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.